Mangoceuticals (MGRX) Cash & Equivalents (2023 - 2026)

Mangoceuticals has disclosed Cash & Equivalents across 4 years of filings, most recently posting $174562.0 for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $174562.0, up 128.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $174562.0 (up 128.2% YoY), and the FY2025 annual result was $1.5 million, changed N/A from the prior year.
• Cash & Equivalents came in at $174562.0 for Q1 2026 at Mangoceuticals, down from $1.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2.9 million in Q2 2023 to a low of $15305.0 in Q1 2024.
• The 4-year median for Cash & Equivalents is $137790.5 (2025), against an average of $701766.6.
• Across the five-year window, Cash & Equivalents surged 399.81% in 2025 and surged 128.2% in 2026, its largest moves.
• Mangoceuticals' Cash & Equivalents stood at $739006.0 in 2023, then tumbled by 90.0% to $73912.0 in 2024, then jumped by 1910.96% to $1.5 million in 2025, then plunged by 88.26% to $174562.0 in 2026.
• The last three Cash & Equivalents figures came in at $174562.0 (Q1 2026), $1.5 million (Q4 2025), and $101019.0 (Q2 2025), per Business Quant data.